Search

Your search keyword '"Yu, Tingmin"' showing total 20 results
Start Over Author "Yu, Tingmin"
20 results on '"Yu, Tingmin"'

1. Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China

Author

Liu, Huanxian, Dong, Ming, Liu, Kaiming, Jia, Zhihua, Gui, Wei, Cheng, Yingying, Lv, Yudan, Qu, Kang, Zhao, Hongru, Chen, Jianjun, Zhang, Dan, Fan, Zhiliang, Yang, Xiaosu, Hu, Dongmei, Xie, Hongyan, Li, Mingxin, Wen, Bing, Chen, Sufen, Xu, Peng, Rong, Qingqing, He, Qiu, Ren, Zhanxiu, Yan, Fanhong, Zhao, Heling, Chen, Min, Yu, Tingmin, Qu, Hongli, An, Xingkai, Guo, Huailian, Zhang, Xinhua, Pan, Xiaoping, Wang, Xiaojuan, Qiu, Shi, Zhang, Lvming, Zhao, Hongling, Pan, Xin, Wan, Qi, Yan, Lanyun, Liu, Jing, Yu, Zhe, Zhang, Mingjie, Ran, Ye, Han, Xun, Yu, Shengyuan, and Dong, Zhao

Published
2023
Full Text
View/download PDF

5. Association between body mass index and medication-overuse headache among individuals with migraine: a cross-sectional study

Author

Liu, Huanxian, primary, Zhao, Hongru, additional, Liu, Kaiming, additional, Jia, Zhihua, additional, Dong, Ming, additional, Cheng, Yingying, additional, Lv, Yudan, additional, Qu, Kang, additional, Gui, Wei, additional, Chen, Jianjun, additional, Zhang, Dan, additional, Fan, Zhiliang, additional, Yang, Xiaosu, additional, Hu, Dongmei, additional, Xie, Hongyan, additional, Li, Mingxin, additional, Wen, Bing, additional, Chen, Sufen, additional, Xu, Peng, additional, Rong, Qingqing, additional, He, Qiu, additional, Ren, Zhanxiu, additional, Yan, Fanhong, additional, Zhao, Heling, additional, Chen, Min, additional, Yu, Tingmin, additional, Qu, Hongli, additional, An, Xingkai, additional, Guo, Huailian, additional, Zhang, Xinhua, additional, Pan, Xiaoping, additional, Wang, Xiaojuan, additional, Qiu, Shi, additional, Zhang, Lvming, additional, Zhao, Hongling, additional, Pan, Xin, additional, Wan, Qi, additional, Yan, Lanyun, additional, Liu, Jing, additional, Yu, Zhe, additional, Zhang, Mingjie, additional, Ran, Ye, additional, Han, Xun, additional, Dong, Zhao, additional, and Yu, Shengyuan, additional

Published
2024
Full Text
View/download PDF

7. The prevalence and clinical features of fibromyalgia in Chinese hospital patients with primary headache: The survey of fibromyalgia comorbid with headache

Author

Dong, Zhao, primary, Liu, Kaiming, additional, Liu, Huanxian, additional, Jia, Zhihua, additional, Gui, Wei, additional, Dong, Ming, additional, Cheng, Yingying, additional, Lv, Yudan, additional, Qu, Kang, additional, Zhao, Hongru, additional, Chen, Jianjun, additional, Zhang, Dan, additional, Fan, Zhiliang, additional, Yang, Xiaosu, additional, Hu, Dongmei, additional, Zhang, Yanbo, additional, Xie, Hongyan, additional, Li, Mingxin, additional, Wen, Bing, additional, Chen, Sufen, additional, Xu, Peng, additional, Rong, Qingqing, additional, He, Qiu, additional, Ren, Zhanxiu, additional, Yan, Fanhong, additional, Zhao, Heling, additional, Chen, Min, additional, Yu, Tingmin, additional, Qu, Hongli, additional, An, Xingkai, additional, Guo, Huailian, additional, Zhang, Xinhua, additional, Pan, Xiaoping, additional, Wang, Xiaojuan, additional, Qiu, Shi, additional, Zhang, Lvming, additional, Zhao, Hongling, additional, Pan, Xin, additional, Wan, Qi, additional, Yan, Lanyun, additional, Liu, Jing, additional, Yu, Zhe, additional, Zhang, Mingjie, additional, Ran, Ye, additional, Han, Xun, additional, and Yu, Shengyuan, additional

Published
2023
Full Text
View/download PDF

8. Efficacy and Safety of Erenumab 70 mg in Adult Patients with Chronic Migraine: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled DRAGON Study (S31.005)

Author

Wang, Shuu-Jiun, primary, Kim, Byung-Kun, additional, Wang, Hebo, additional, Zhou, Jiying, additional, Wan, Qi, additional, Yu, Tingmin, additional, Lian, Yajun, additional, Arkuszewski, Michal, additional, Ecochard, Laurent, additional, Wen, Shihua, additional, Yin, Fangfang, additional, Li, Zheng, additional, Su, Wendy, additional, and Yu, Shengyuan, additional

Published
2022
Full Text
View/download PDF

9. Additional file 1 of A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Author

Yu, Shengyuan, Kim, Byung-Kun, Wang, Hebo, Zhou, Jiying, Wan, Qi, Yu, Tingmin, Lian, Yajun, Arkuszewski, Michal, Ecochard, Laurent, Wen, Shihua, Yin, Fangfang, Li, Zheng, Su, Wendy, and Wang, Shuu-Jiun

Abstract

Additional file 1: Supplementary Table 1. Definitions used in the study. Supplementary Table 2. Details of eligibility criteria. Supplementary Table 3. Patient reported outcome tool: mMIDAS. Supplementary Table 4. Change from baseline in MMD by visit, observed,mixed model repeated measures (full analysis set). Supplementary Table 5. Patientincidence rates of treatment-emergent SAEs in the study by primary SOC (Safety analysis set).

Published
2022
Full Text
View/download PDF

18. Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial

Author

Cao, Kegang, primary, Han, Fang, additional, Lin, Anji, additional, Yang, Wenming, additional, Zhao, Jianjun, additional, Zhang, Hui, additional, Ding, Yanbing, additional, Xie, Wei, additional, Xu, Yinping, additional, Yu, Tingmin, additional, Wang, Xinzhi, additional, Yang, Xiaosu, additional, Zhou, Jiying, additional, Hou, Qun, additional, Yu, Lihua, additional, and Gao, Ying, additional

Published
2016
Full Text
View/download PDF

19. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache

Author

Yu, Shengyuan, primary, Hu, Yueqing, additional, Wan, Qi, additional, Zhou, Jiying, additional, Liu, Xinfeng, additional, Qiao, Xiangyang, additional, Yang, Xiaosu, additional, Feng, Jiachun, additional, Chen, Kangning, additional, Pan, Xiaoping, additional, Yang, Qingwu, additional, Dou, Linsen, additional, Liu, Ming, additional, Chen, Yangmei, additional, Yu, Tingmin, additional, Yu, Juming, additional, Li, Zhiwei, additional, Bai, Xue, additional, and Duan, Jingfeng, additional

Published
2015
Full Text
View/download PDF

20. Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.

Author

Wang, Shuu‐Jiun, Kim, Byung‐Kun, Wang, Hebo, Zhou, Jiying, Wan, Qi, Yu, Tingmin, Lian, Yajun, Arkuszewski, Michal, Ecochard, Laurent, Snellman, Josefin, Wen, Shihua, Yin, Fangfang, Li, Zheng, Su, Wendy, and Yu, Shengyuan

Abstract

Background Objective Methods Results Conclusions Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).Reversion from CM to EM was defined as a reduction in headache frequency to < 45 headache days over the 12 weeks of the double‐blind treatment period. In addition, migraine‐related disability and disease impact on functional impairment were assessed within each treatment group in reverters and non‐reverters using the Headache Impact Test‐6 (HIT‐6), Migraine Physical Function Impact Diary (MPFID), and modified Migraine Disability Assessment (mMIDAS).Overall, 557 patients with CM were randomized to monthly erenumab 70 mg (n = 279) or placebo (n = 278), of whom 52.3% (146 of 279) treated with erenumab reverted from CM to EM compared to 41.0% (114 of 278) in the placebo group (odds ratio [OR] 1.59, 95% confidence interval: 1.1–2.2; p = 0.007). Treatment with erenumab resulted in a greater mean change (standard error) from baseline in the HIT‐6 total score for reverters versus non‐reverters compared to placebo (erenumab: −9.5 [0.6] vs. −5.1 [0.5]; placebo: −8.9 [0.7] vs. −4.9 [0.5]). A similar pattern was observed for mMIDAS score in erenumab treatment groups versus placebo (erenumab: −22.1 [1.2] vs. −6.3 [1.8]; placebo: −19.9 [1.3] vs. −7.9 [1.6]). Substantial improvements were reported in MPFID‐Physical Impairment (PI) and Everyday Activities (EA) scores in reverters versus non‐reverters in erenumab treatment groups (MPFID‐PI: −5.9 [0.3] vs. −1.9 [0.6]; MPFID‐EA: −7.9 [0.4] vs. −3.4 [0.6]) and in placebo (MPFID‐PI: −5.4 [0.4] vs. −1.0 [0.5]; MPFID‐EA: −7.1 [0.5] vs. −3.2 [0.5]).This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient‐reported outcomes in the erenumab group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results